William Blair Investment Management LLC Raises Stake in Haemonetics Co. (NYSE:HAE)

William Blair Investment Management LLC grew its stake in shares of Haemonetics Co. (NYSE:HAE) by 29.6% in the fourth quarter, Holdings Channel reports. The firm owned 446,258 shares of the medical instruments supplier’s stock after acquiring an additional 101,807 shares during the period. William Blair Investment Management LLC’s holdings in Haemonetics were worth $34,844,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Arizona State Retirement System boosted its stake in shares of Haemonetics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock valued at $1,160,000 after purchasing an additional 181 shares during the period. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the period. HighTower Advisors LLC grew its holdings in Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock worth $262,000 after acquiring an additional 244 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in Haemonetics by 0.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier’s stock worth $5,033,000 after acquiring an additional 407 shares in the last quarter. Finally, Isthmus Partners LLC grew its holdings in Haemonetics by 1.1% during the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier’s stock worth $3,140,000 after acquiring an additional 450 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on HAE shares. Raymond James reiterated a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Stock Down 0.2 %

NYSE:HAE opened at $64.69 on Wednesday. The stock has a market capitalization of $3.25 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company’s 50-day simple moving average is $68.08 and its 200-day simple moving average is $75.26. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.